Nektar Therapeutics

0UNL.LSE▼

Nektar's Billion-Dollar Cash Faces Multi-Year Test as Phase 3 Trials Advance

Nektar Therapeutics reported a second-quarter net loss of $40.6 million, or $1.23 per share, as it advances its lead drug candidate rezpegaldesleukin into Phase 3 trials for atopic dermatitis and alopecia areata, with a $1.02 billion cash balance providing runway into 2028. The company is enrolling patients in two pivotal atopic dermatitis studies, each with 510 patients, and a third study is set to start by the end of September 2026, with top-line data expected in mid-2028 and a Biologics License Application submission in 2029. For alopecia areata, a single registrational Phase 3 study will enroll 850 patients with a primary endpoint of 80% or more scalp hair coverage at week 52. Operating loss widened to $42.3 million from $36.2 million a year earlier, and full-year R&D guidance is now $210 million to $230 million, while revenue remains minimal at $10.1 million in noncash royalty income. The company raised $373.8 million in gross proceeds from a public offering in April 2026, but faces a jury trial in federal court in San Francisco starting September 8, 2026, and short interest stands at 19.92% of the float.

NKTR ▼

Insider Monkey·22dRead more →

Biotech & Genomic Medicine▲2

Nektar Q2 Loss Narrows, Revenue Misses, Pipeline Advances

Nektar Therapeutics reported a second-quarter 2026 loss of $1.23 per share, much narrower than the Zacks Consensus Estimate of a loss of $2.06 and the year-ago loss of $2.95 per share. Total revenues came in at $10.1 million, down 9.8% year over year and missing the consensus estimate of $11 million. The company's top line now consists solely of non-cash royalty revenues following the December 2024 sale of its Huntsville manufacturing facility. Nektar expects 2026 non-cash royalty revenues of $40-$45 million, R&D costs of $210-$230 million, G&A expenses of $60-$65 million, and year-end cash of approximately $815-$840 million. The company's lead candidate rezpegaldesleukin, or rezpeg, is advancing with two phase III studies in atopic dermatitis initiated last month and a third study scheduled to begin in September, with top-line data expected in mid-2028.

NKTR ▲

Biotech & Genomic Medicine

Zacks Investment Research·35dRead more →

0UNL.LSE▲

Applied Materials, Nektar, StoneCo Report Quarterly Results

Applied Materials, Nektar Therapeutics, and StoneCo reported quarterly results, with Applied Materials posting adjusted earnings of $3.5 per share on revenues of $9.12 billion, beating the Zacks Consensus Estimate of $3.38 per share. Nektar Therapeutics reported a narrower-than-expected adjusted loss of $1.23 per share on revenues of $10.13 million, while StoneCo posted adjusted earnings of $0.47 per share on revenues of $709.88 million. The reports come as Wall Street heads for a winning week in which the S&P 500 recorded a new all-time high, and the Commerce Department said retail sales decreased 0.6% in July. After the closing bell, the University of Michigan will report its preliminary August consumer sentiment index, and the Census Bureau will release June business inventories data.

AMAT ▲NKTR ▲

Zacks Investment Research·35dRead more →

Biotech & Genomic Medicine

Syndax Tops Biotech Takeover Watchlist After AbbVie's Apogee Deal

Syndax Pharmaceuticals ranks as the most likely biotech takeover target following AbbVie's acquisition of Apogee Therapeutics, according to a Wall Street analysis. With a market cap of roughly $1.71 billion, Syndax is the smallest of three highlighted Nasdaq-listed firms and already has two FDA-approved drugs, Revuforj and Niktimvo, generating $64.86 million in total first-quarter revenue, up 223.6% year over year. Its co-commercialization partner Incyte is named as the most logical acquirer, while Nektar Therapeutics and Viking Therapeutics are seen as less urgent targets due to their larger cash reserves and market caps. The Apogee deal has reignited merger and acquisition speculation across the biotech sector, with buyers seeking late-stage clinical data, large addressable markets, and strategic fit in immunology, obesity, or oncology.

APGE ▲SNDX ▲INCY ▲ABBV ▲NKTR VKTX

Biotech & Genomic Medicine

Yahoo Finance·87dRead more →